Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
Epistemonikos ID: d4fa407dda31dda5f3254d74567d3f439c55a49e
First added on: May 08, 2024